EUDAMED Status Update 2021
The development and deployment of EUDAMED is progressing. Following the implementation plan and getting familiar with the information stored in the database's modules is crucial for economic operators compliance in the EU market.

EUDAMED is the IT system developed by the European Commission to implement Regulation (EU) 2017/745 on medical devices and Regulation (EU) 2017/746 on in vitro diagnosis medical devices.

The system database is multipurpose, interoperable and structured around 6 interconnected modules and a public website:

  • Actor Registration – ACT
  • Unique Device Identification/Devices Registration – UDI
  • Notified Bodies and Certificates – CRF
  • Clinical Investigations and Performance Studies – CIPS
  • Vigilance and Post-Market Surveillance – VGL
  • Market Surveillance – MSU

What is stored in the EUDAMED?

Module ACT – Actor Registration

This module allows actors – manufacturers, system & procedure pack producers, importers and EU authorised representatives – to register. When an economic operator has submitted its actor registration request, the selected relevant national competent authority issues the Actor ID/ Single Registration Number (SRN) generated by EUDAMED, after approving the registration request. Actors are clearly identified through the SRN. After registration and verification of the data provided, the actors will have access to EUDAMED. 

Since the 1st December 2020 all actor information registered in EUDAMED are publicly available.

At the moment the European Commission is not in a position to require the use of the Actor registration module until EUDAMED is fully functional according to the Medical Device Regulation and additional national requirements on registrations can therefore not be excluded.

Module UDI – Unique Device Identification/Devices Registration

The UDI module contains all device-specific information. The UDI data is divided into BASIC UDI-DI and the UDI-DI. The BASIC UDI-DI serves to map all common properties of a product group. The UDI-DI contains only the product-specific information. 

As an economic operator, you are responsible for managing all UDI attributes in your own company and transferring the data to EUDAMED.

Information on the registered Basic UDI-DI, UDI-DI and Device are publicly available.

Module CRF – Notified Bodies and Certificates

Certificates issued by Notified Bodies on Quality Management System and Conformity Assessment in accordance with MDR 2017/745 and IVDR 2017/746 are stored in this module. The module is used to enable communication between the Notified Bodies and to monitor the status of the consultation procedures for clinical evaluations.

Public access will be granted to the registration of certificates of conformity, their scope and validity period, as well as the reports of the Notified Bodies on the SSCP.

Module CIPS – Clinical Investigations and Performance Studies 

This module will be used to manage clinical investigation and performance evaluation data. Besides, applications for clinical performance studies and trials can be submitted, as well as clinical follow-ups and post-market product changes and reports.

Clinical Investigation Registration, Clinical Investigation Results Reporting and Publication are accessible to the public. Clinical Investigation Application Documents will potentially be accessible by the public.

Module VGL – Vigilance and Post-Market Surveillance 

Several reports can be submitted via the Vigilance Module: Periodic Safety Update Report (PSUR; Periodic Summary Reports (PSR) and Reporting of Serious Incidents and Field Safety Corrective Actions (FSCAs) and Field Safety Notices (FSNs). FSCAs are automatically distributed to the appropriate authorities after they are reported in the Vigilance Module. 

Partial public access for manufacturer incident reports and Field Safety Notices.

Module MSUMarket Surveillance

This module is designed to facilitate cooperation and coordination between competent authorities of EU Member States.

Public may access the summary of the results of the reviews and assessments of the market surveillance activities.

What is the state of play of the implementation of EUDAMED?

The development and deployment of EUDAMED is progressing:

The module on Actor Registration (first module) went live in December 2020.

The module on UDI/Device Registration (second module) and the module on Notified Bodies and Certificates (third module) are available since October 2021 except for the mechanism for scrutiny and the clinical evaluation consultation procedure (CECP) functionalities. 

The remaining three modules – Clinical Investigations and Performance Studies, Vigilance and Post-Market Surveillance and Market Surveillance – as well as the mechanism for scrutiny and the CECP will be launched when EUDAMED is fully operational in May 2022.

References: European Commission – Medical Devices – EUDAMED. Available at:


medical devices

Safety Reporting in Clinical Investigations: a Gap Analysis of Guidance Documents 

Safety reporting in clinical investigations of medical devices shall be performed in line with Article 80(2) of the EU MDR. On May 2020, it was published the MDCG 2020-10/1, outlining the procedures for safety reporting in clinical investigations of medical devices under the EU MDR. However, on October 2022 the Medical Device Coordination Group (MDCG) published an updated version of the MDCG 2020-10/1, the MDCG 2020-10/1 Rev 1. This article highlights the updates included in the new revision, analysing the gaps between both documents.

Read More »
medical devices

Roles and Responsibilities of an Authorised Representative under EU MDR and IVDR 

If a medical device manufacturer is not established in a Member State, the devices can only be placed on the Union market if the manufacturer designates an authorised representative. The authorised representative plays a pivotal role in ensuring the compliance of the devices with EU regulation, serving as point of contact. The obligations and responsibilities of authorised representative are outlined on Article 11 of both MDR and IVDR, but clarification of relevant requirements is described in MDCG 2022-16 of October 2022.

Read More »
medical devices

Understanding the ISO Standards Lifecycle

ISO Standards cover a huge range of activities, representing the distilled wisdom of people with expertise in their subject matter and providing the regulators with a sound basis to develop better legislation. ISO Standards are diverse, addressing from the shoe size we wear to the quality of air we breathe. The medical device sector is no exception. ISO has many International Standards and guidance documents aimed at helping the sector ensure safe and effective medical devices while meeting the multitude of national, regional and international regulatory requirements. But how exactly is a Standard developed, reviewed and withdraw?

Read More »
medical devices

Amendments to the Transitional Provisions of the European Union MDR and IVDR

The proposed amendments aim to maintain patients’ access to a wide range of medical devices while ensuring the transition to the new framework. The ammendments proposal aims to extend the current transition period (Article 120 of the MDR), and it also deletes the ‘sell-off’ deadlines of both MDR and IVDR. The extension is staggered depending on the risk class of the device – until December 2027 for high-risk devices and December 2028 for medium and lower-risk devices.

Read More »
medical devices

EU MDR – Proposal for Extension of Transition Period

The transition to MDR has been slower than anticipated by the European Commission. Insufficient capacity of notified bodies and the low level of preparedness of manufacturers led to a proposal for extension of current MDR transition period with deadlines depending on the risk class of the devices.

Read More »
medical devices

MDCG 2022-18 – EU MDR Article 97

EU MDR Article 97 may be a temporary solution to avoid disruption of supply of Medical Devices on the EU Market. The MDCG 2022-18 presents a uniform approach for application of MDR Article 97 on non-compliant legacy devices under the conditions set by the competent authorities, while limiting the impact on the supply of safe and effective devices.

Read More »
cosmetic products

EU to set Labelling Requirements for 56 additional Fragrance Allergens in Cosmetic Products

World Trade Organization (WTO) has been notified by the European Commission of a draft amendment to Regulation (EC) No 1223/2009 as regards labelling of fragrance allergens in Cosmetic Products. The proposed date of adoption of the new regulation is expected to be in the first half of 2023 and the propose date of entry in force 20 days from the publication in the Official Journal of the European Union.

Read More »
cosmetic products

New Amendments to the European Cosmetics Regulation – CMR Substances

The European Commission published the Commission Regulation (EU) 2022/1531, which amends Regulation (EC) No 1223/2009 in regards to the use in cosmetic products of certain substances classified as CMR. This amendment introduces new entries to Annex II and Annex III and revises an entry to Annex V to Regulation (EC) No 1223/2009.

Read More »